A study of coagulation profile in patients with cancer in a tertiary care hospital

Khichariya, Gaurav; Manjula, K; Das, Subhashish; Kalyani, Rita R.

doi:10.29328/journal.jhcr.1001015

Cited by 1 publication

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is something that should be kept in mind. A study that was conducted in India found that the levels of fibrinogen, prothrombin time, and activated partial thromboplastin time in cervical cancer patients were much higher than those seen in healthy control participants [42,43] .This shows the importance of using this test for prognosis. Similar results were found in an Iranian, Korean, and Indonesian investigation, which found that cervical cancer patients had much higher D-dimer levels than healthy controls.…”

Section: Current Standards For Hemostasiological Indicators Of Blood ...mentioning

confidence: 99%

Diagnostics of hemostasiological indicators of blood in patients with cervical cancer: standards, innovative models of the future (Ukraine)

2022

FEM

View full text Add to dashboard Cite

This article focused on “Diagnostics of hemostasiological indicators of blood in patients with cervical cancer: standards, innovative models of the future (Ukraine)”. Aims: The aims of this study are to investigate the current standards, the innovative models, prognostic and predictive value of hemostasiological indicators of blood in patients with cervical cancer and identifications of potential gaps and opportunities in the current standards and innovative models for hemostasiological assessment. Methodology: A descriptive cross-sectional study design was evaluated. Secondary data were collected. Descriptive statistics were obtained and utilised. Results: The result showed that in 2020, Ukraine had 20.3 new cervical cancer cases per 100,000 women, regardless of age. Age-standardised cervical cancer incidence was 14.3 per 100,000 women. In 2020, Ukraine's lifetime cervical cancer risk was 1.4%. It illustrates cervical cancer risk. Prothrombin Time is 11–14 seconds, Activated Partial Thromboplastin Time is 25–35 seconds, fibrinogen is 200–400 mg/dL, and platelet counts are 150,000–450,000/L. Thromboelastography is a viscoelastic test that dynamically assesses blood clot formation, strength, and lysis. This test helps doctors assess cervical cancer patients' haemostatic profile and thrombotic risk and establish thromboprophylaxis regimens. In advanced cervical cancer patients, prothrombin time, APTT, fibrinogen, D-dimer, and platelet count predict thrombotic events and poor prognosis. These signs extend VTE risk. Potential gaps or opportunities include a lack of established practices, few complicated hemostasiological tests, little research, lack of knowledge and teaching, and difficulties with monitoring and follow-up, especially in resource-poor areas. Standardising techniques, expanding access to cutting-edge hemostasiological tests, and remote monitoring, and running education and awareness campaigns are future potentials for research and development. Scientific Novelty: cutting-edge hemostasiological tests in cervical cancer. Conclusion: In conclusion, resolving global cervical cancer mortality disparities needs healthcare, cancer prevention, screening, awareness, socioeconomic variables, and creative hemostasiological evaluation models. Better care, thromboprophylaxis, and collaboration can improve cervical cancer outcomes worldwide.

show abstract

Section: Current Standards For Hemostasiological Indicators Of Blood ...mentioning

confidence: 99%

Diagnostics of hemostasiological indicators of blood in patients with cervical cancer: standards, innovative models of the future (Ukraine)

2022

FEM

View full text Add to dashboard Cite

show abstract

A study of coagulation profile in patients with cancer in a tertiary care hospital

Cited by 1 publication

References 15 publications

Diagnostics of hemostasiological indicators of blood in patients with cervical cancer: standards, innovative models of the future (Ukraine)

Diagnostics of hemostasiological indicators of blood in patients with cervical cancer: standards, innovative models of the future (Ukraine)

Contact Info

Product

Resources

About